热门资讯> 正文
KeyBanc的Solventum因实现长期增长目标而升级
2026-01-27 02:24
- KeyBanc Capital Markets has upgraded Solventum (SOLV) to overweight from sector weight as the 3M spinoff is on the right track to achieving long-term growth targets.
- The bank has a $97 price target (~23% upside based on Jan. 23 close).
- "Given new product launches, growth accretive M&A, a steady macro backdrop, and the annualization of SKU headwinds in 2027, we think SOLV could potentially track closer to its 4-5% organic growth objective ahead of its 2028 timeline," analyst Brett Fishbin wrote.
- He added that concerns over 2026 guidance "may be overblown" and the company has moved into an offensive capital allocation strategy.
- Fishbin noted that given he has an 11.4x 2027 EPS estimate multiple, it positions Solventum with an attractive valuation compared to its peers, which trade at an average 2027 multiple of ~15x.
More on Solventum Corporation
- Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not
- Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Solventum: Setting Up For Growth And A Re-Rating
- Solventum is the top performing healthcare supplies stock YTD
- Solventum to buy private wound care firm Acera for up to $850M
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
